Related Experiment Videos
[Topotecan-based combined chemotherapy for refractory or relapsed hematologic malignancies]
De-pei Wu1, Xiao-wen Tang, Ai-ning Sun
1Department of Hematology, First Hospital of Suzhou University, Jiangsu Institute of Hematology, Suzhou 215006, China.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|December 24, 2003
Summary
Topotecan-based chemotherapy shows significant anti-tumor activity in relapsed or refractory hematologic malignancies. This salvage therapy demonstrated a 61.9% response rate with manageable toxicity.
Area of Science:
- Hematology
- Medical Oncology
- Pharmacology
Context:
- Refractory or relapsed hematologic malignancies present significant treatment challenges.
- Salvage chemotherapy aims to induce remission in patients with resistant or recurrent cancers.
- Topotecan is a topoisomerase I inhibitor with known anti-cancer properties.
Purpose:
- To evaluate the efficacy and toxicity of topotecan-based combined chemotherapy.
- To assess the response rate and adverse events in patients with refractory/relapsed hematologic malignancies receiving topotecan combination therapy as salvage treatment.
Summary:
- Twenty-one patients with acute leukemia, non-Hodgkin's lymphoma, or myelodysplastic syndrome received a single course of topotecan combined with cytarabine, amsacrine, or cyclophosphamide.
- The overall response rate was 61.9%, including 42.9% complete remission (CR) and 19% partial remission (PR).
- Severe myelosuppression occurred in all patients, with a median agranulocytic period of 12.6 days in acute leukemia and 7.5 days in non-Hodgkin's lymphoma. Febrile infections were noted in 15 patients, while non-hematologic toxicity was mild.
Impact:
- Topotecan-based combined chemotherapy demonstrates significant antitumour activity in high-risk hematologic malignancies.
- This regimen offers a viable salvage therapy option with acceptable toxicity profiles.
- The findings support the use of topotecan combinations for patients with refractory or relapsed hematologic cancers who have limited treatment alternatives.